These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15911475)

  • 1. More on data monitoring and large apparent treatment effects.
    Anderson JR
    Contemp Clin Trials; 2005 Jun; 26(3):416-7. PubMed ID: 15911475
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring and large apparent treatment effects.
    Korn EL; Freidlin B; George SL
    Control Clin Trials; 2004 Feb; 25(1):67-9; author reply 71-2. PubMed ID: 14980749
    [No Abstract]   [Full Text] [Related]  

  • 5. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 6. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 9. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.
    Wheatley K; Clayton D
    Control Clin Trials; 2003 Feb; 24(1):66-70. PubMed ID: 12559643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stopping rules for clinical trials.
    Whitehead J
    Control Clin Trials; 2004 Feb; 25(1):69-70; author reply 71-2. PubMed ID: 14980750
    [No Abstract]   [Full Text] [Related]  

  • 14. Problems with up-front randomization in clinical trials.
    Wheatley K; Hills RK; Burnett AK
    J Clin Oncol; 2006 Dec; 24(34):5471-2; author reply 5472-3. PubMed ID: 17135654
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancing the validity and utility of randomized clinical trials in addictions treatment research: III. Data processing and statistical analysis.
    Del Boca FK; Darkes J
    Addiction; 2007 Sep; 102(9):1356-64. PubMed ID: 17511751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trials in oncology stopped early for benefit.
    Wilcox RA; Djulbegovic B; Moffitt HL; Guyatt GH; Montori VM
    J Clin Oncol; 2008 Jan; 26(1):18-9. PubMed ID: 18165635
    [No Abstract]   [Full Text] [Related]  

  • 17. Discussion of "Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data".
    Small DS; Cheng J
    Biometrics; 2009 Sep; 65(3):682-6; discussion 689-91. PubMed ID: 18759846
    [No Abstract]   [Full Text] [Related]  

  • 18. Invited commentary for "From innumeracy to insight: the uncertainty of help versus harm in treatment of asymptomatic aortic aneurysms" by Legemate and Bossuyt.
    Björck M; Wanhainen A
    Eur J Vasc Endovasc Surg; 2006 Dec; 32(6):624-6. PubMed ID: 16931072
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.
    Shrier I
    Stat Med; 2008 Jun; 27(14):2740-1; author reply 2741-2. PubMed ID: 18069729
    [No Abstract]   [Full Text] [Related]  

  • 20. Using causal models to show the effect of untestable assumptions on effect estimates in randomized controlled trials.
    Allard R; Boivin JF
    Clin Trials; 2007; 4(6):611-20. PubMed ID: 18042570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.